A Study to Evaluate the Safety and Use of Human Rhinovirus in Healthy and Asthmatic Participants (MK-0000-218)

NCT01866306 | Completed Phase 1 Results

• 2 other identifiers: 0000-2182013-000618-39
• Study Type: interventional
• Target: 59
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to establish the safety and tolerability of Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) human rhinovirus 16 (RV16UB) in healthy and asthmatic participants, and to identify an appropriate dosage of RV16UB in order to study biomarkers in asthmatic participants. The study is divided into 2 parts. Part 1 is a dose-finding study where healthy participants, and asthmatic participants, who were either treated or not treated with a class of long-acting beta antagonists (LABA) will be recruited to undergo nasal challenge with increasing doses of RV16UB. Part 2 is a biomarker study where mild to moderate asthmatics undergo challenge with the most appropriate dose of RV16UB identified in Part 1, based on tolerability and viral effects. .

Conditions

Asthma

Outcome Measures

Primary Outcomes (7)

• Number of Healthy and Asthmatic Participants With Events of Clinical Interest (ECI) (Part 1)

  ECI are selected non-serious and serious adverse events which include the following: an overdose of Sponsor's product; requirement for systemic steroids to treat asthma exacerbation related to virus challenge; acute reaction to virus challenge, confirmed through repeat measurement and when considered potentially associated with administration of virus; specified vital sign findings within 4hr of challenge; specified symptom findings within 24hr of challenge; \>20% decrease in Forced Expiratory Volume in 1 second (FEV1) relative to baseline within 4hr of challenge; dyspnea associated with drop in FEV1 (within 4hr of challenge) that is unresponsive to a bronchodilator rescue agent within 20 minutes; Grade 2+ deviation from normal values of liver-related laboratory parameters at any time between challenge and day 14.

  Up to Day 24

• Number of Participants With Serious Adverse Events (SAE) (Parts 1 and 2)

  A SAE is any adverse event occurring at any dose or during any use of the Sponsor's product that: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing in-patient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event.

  Up to Day 24

• Number of Asthmatic Participants Treated With a Viral Dose of 100 TCID50 With Challenge Induced Upper Airway Symptoms (Part 1)

  Asthmatic participants from Part 1 were treated with RV16UB virus at a dose of 100 TCID50, and challenge induced upper airway symptoms were monitored with a diary recording Jackson Cold Symptom Score (CSS). The CSS measures 8 cold symptoms, with each symptom scored from 0 (absent) to 3 (severe). The total score ranges from 0-24, with higher scores reflecting greater severity. The number of participants with a CSS score equal or greater than 3 for two days in a row are presented.

  Day 1 up to Day 7

• Time -Weighted Average (TWA) Percent Change From Baseline (CFB) in Morning FEV1 in Asthmatic Participants on Days 1-7 (Part 2)

  Log-transformed FEV1 data were fit by Bayesian hierarchical longitudinal models, with a random participant effect and a fixed categorical effect for day. All baseline (day -7 to day -1) FEV1 were assumed to be with equal mean. FEV1 assessments obtained between 3 am to 3 pm were counted as morning measurements. The TWA CFB morning FEV1 on days 1-7 was calculated as the difference of the mean of estimated day 1-7 morning FEV1 value and the corresponding estimated baseline value. The 95% Confidence Interval actually refers to a 95% Credible Interval. The anticipated mean reduction from baseline is 10%.

  Baseline and Days 1 - 7

• TWA Percent CFB in Evening FEV1 in Asthmatic Participants on Days 1-7 (Part 2)

  Log-transformed FEV1 data were fit by Bayesian hierarchical longitudinal models, with a random participant effect and a fixed categorical effect for day. All baseline (day -7 to day -1) FEV1 were assumed to be with equal mean. FEV1 assessments obtained between 3 pm to next day 3 am were counted as evening measurements. The TWA CFB evening FEV1 on days 1-7 was calculated as the difference of the mean of estimated day 1-7 evening FEV1 value and the corresponding estimated baseline value. The FEV1 readings on the evenings of sputum inductions were excluded from the analyses. The 95% Confidence Interval actually refers to a 95% Credible Interval. The anticipated mean reduction from baseline is 10%.

  Baseline and Days 1- 7

• Change From Baseline in Mean Maximum Jackson Cold Symptom Score (CSS) on Days 1 to 14 in Asthmatic Participants (Part 1)

  Asthmatic participants from Part 1 were treated with RV16UB virus, and challenge induced upper airway symptoms were monitored with a diary recording CSS. The CSS measures 8 cold symptoms, with each symptom scored from 0 (absent) to 3 (severe). The total score ranges from 0-24, with higher scores reflecting greater severity, and a positive change from baseline indicating worsening symptoms.

  Baseline and Days 1 - 14

• Number of Asthmatic Participants Demonstrating at Least 10^3 Copies/ml of Viral RNA in Nasal Lavage Fluid on Days 1 to 14 (Part 1)

  Viral RNA was measured by real time reverse transcriptase polymerase chain reaction (qRT-PCR) from nasal lavage fluid collected on day 3 and day 7 from asthmatic participants, and the number of participants with at least 10\^3 copies/ml was determined.

  Days 1 - 14

Secondary Outcomes (2)

• Mean Percent Change From Baseline in Maximum Drop FEV1 of Asthmatic Participants (Part 2)

  Baseline and up to day 7

• Mean Change From Baseline in TWA Asthma Control Diary (ACD) Score of Asthmatic Participants on Days 3 to 10 (Part 2)

  Baseline and Days 3 to 10

Study Arms (7)

Healthy 10 TCID50 (Part 1)

EXPERIMENTAL

Healthy participants were treated with 10 Tissue Culture Infective Dose 50 (TCID50) administered by spraying an atomized viral suspension of RV16UB into a single nostril.

Biological: RV16UB

Healthy 100 TCID50 (Part 1)

EXPERIMENTAL

Healthy participants were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.

Biological: RV16UB

Healthy 1000 TCID50 (Part 1)

EXPERIMENTAL

Healthy participants were treated with 1000 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.

Biological: RV16UB

Asthmatic non-LABA 10 TCID50 (Part 1)

EXPERIMENTAL

Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 10 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.

Biological: RV16UB

Asthmatic non-LABA 100 TCID50 (Part 1)

EXPERIMENTAL

Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.

Biological: RV16UB

Asthmatic LABA 100 TCID50 (Part 1)

EXPERIMENTAL

Participants with mild to moderate asthma, concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.

Biological: RV16UB; Drug: LABA

Asthmatic non-LABA 100 TCID50 (Part 2)

EXPERIMENTAL

Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.

Biological: RV16UB

Interventions

RV16UB BIOLOGICAL

RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.

Asthmatic LABA 100 TCID50 (Part 1); Asthmatic non-LABA 10 TCID50 (Part 1); Asthmatic non-LABA 100 TCID50 (Part 1); Asthmatic non-LABA 100 TCID50 (Part 2); Healthy 10 TCID50 (Part 1); Healthy 100 TCID50 (Part 1); Healthy 1000 TCID50 (Part 1)

LABA DRUG

Asthmatic participants were treated with LABA as part of their standard of care

Asthmatic LABA 100 TCID50 (Part 1)

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Parts 1 and 2:
• have a Body Mass Index (BMI) between =\< 35 kg/m\^2 and \> 17 kg/m\^2
• female of childbearing potential is not pregnant and agrees to use 2 acceptable methods of birth control until 10 days after the last visit,; or female is of non-childbearing potential
• is a non-smoker, or has not smoked within prior 12 months, with a history of =\< 10 pack-years
• Part 1:
• Either of the following:
• healthy (may have out-of season seasonal allergies)
• mild to moderate-asthmatic with a history of spontaneous or exertional wheezing; and with all of the following for \> 4 weeks prior: daytime symptoms twice weekly or less, no activity limitation, no nocturnal symptoms, uses reliever treatment twice daily or less, with an unchanged asthma medication dose, and uses inhaled corticosteroid (ICS) at a stable dose-equivalent of =\< 500 mcg/day fluticasone propionate
• Part 2:
• mild to moderate-asthmatics only with a history of spontaneous or exertional wheezing; and with all of the following for \> 4 weeks prior: daytime symptoms twice weekly or less, no activity limitation, no nocturnal symptoms, uses reliever treatment twice daily or less, with an unchanged asthma medication dose, and uses ICS at a stable dose-equivalent of =\< 500 mcg/day fluticasone propionate
• had a mild change in symptoms associated with viral syndrome, leading to temporarily increased short acting beta agonist use or increased ICS dose within the past 5 years

You may not qualify if:

• has a history of severe or difficult to manage allergies (e.g. food, drug, latex)
• has a history of asthma-related ventilatory failure in adolescence or adulthood
• is positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV)
• has significant nasal septum deviation, nasal polyps or other nasal anatomical abnormality
• shares the same household or has intimate contact with an infant, pregnant or lactating woman, or immunosuppressed individual
• has a history or current evidence of any upper or lower respiratory tract infection within 6 weeks prior to baseline assessment
• had major surgery or lost 1 unit (500 mL) of blood within prior 4 weeks
• has participated in another investigational trial within the prior 10 weeks
• is pregnant or a nursing mother
• uses excluded prescription or non-prescription medications within 2 weeks prior to initial viral challenge and throughout the trial

Sponsors & Collaborators

• Merck Sharp & Dohme LLC: lead
• U-BIOPRED Consortium: collaborator

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Results Point of Contact

• Title: Senior Vice President, Global Clinical Development
• Organization: Merck Sharp & Dohme Corp.

ClinicalTrialsDisclosure@merck.com

1-800-672-6372

Study Officials

• Medical Director

  Merck Sharp & Dohme LLC

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 28, 2013
• First Posted: May 31, 2013
• Study Start: October 22, 2013
• Primary Completion: December 25, 2015
• Study Completion: January 18, 2016
• Last Updated: September 4, 2018
• Results First Posted: March 13, 2017

Record last verified: 2018-08

Data Sharing

• IPD Sharing: Will share